Median Technologies Future Growth

Future criteria checks 2/6

Median Technologies is forecast to grow earnings and revenue by 8.7% and 35.9% per annum respectively while EPS is expected to grow by 13.3% per annum.

Key information

8.7%

Earnings growth rate

13.3%

EPS growth rate

Healthcare Services earnings growth	28.7%
Revenue growth rate	35.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Mar 14

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Jan 03

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Jul 14

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

May 05

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

May 07

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Dec 28

Earnings and Revenue Growth Forecasts

ENXTPA:ALMDT - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	46	-19	-17	-18	4
12/31/2024	30	-26	-25	-25	4
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	-16	-16	N/A
12/31/2017	8	-17	-14	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A
9/30/2013	1	-4	N/A	N/A	N/A
6/30/2013	1	-4	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALMDT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALMDT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALMDT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALMDT's revenue (35.9% per year) is forecast to grow faster than the French market (5.7% per year).

High Growth Revenue: ALMDT's revenue (35.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALMDT's Return on Equity is forecast to be high in 3 years time

Median Technologies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 25% to €24.40

Price target decreased by 22% to €19.47

Consensus revenue estimates fall by 12%

Price target decreased by 15% to €29.03

Forecast to breakeven in 2025

Consensus EPS estimates fall by 16%

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Price target increased by 25% to €24.40

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Price target decreased by 22% to €19.47

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Consensus revenue estimates fall by 12%

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Price target decreased by 15% to €29.03

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Consensus EPS estimates fall by 16%

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

Full year 2021 earnings: EPS misses analyst expectations

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Price target increased to €28.10

Price target increased to €28.10

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

New 90-day high: €13.50

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

New 90-day high: €9.18

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Median Technologies Announces the Results of Preliminary Retrospective Study on the Evaluation of the Severity of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis

First half earnings released

New 90-day high: €8.98

New 90-day high - €8.38

Median Technologies SA to Report First Half, 2020 Results on Oct 14, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies